Regulatory securities lawsuit

Corcept Therapeutics Faces Securities Lawsuit Over Relacorilant

Analysis based on 252 articles · First reported Jan 29, 2026 · Last updated Apr 17, 2026

Sentiment

-40

Attention

Articles

252

Market Impact

Direct

Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard

Market Impact

The market is negatively impacted by the significant drop in Corcept Therapeutics's stock price, reflecting investor concern over drug approval processes and corporate transparency. This event highlights the risks associated with pharmaceutical development and the potential for substantial losses when regulatory hurdles are not met.

Pharmaceuticals Legal Services

Event Summary

Corcept Therapeutics is facing a securities class action lawsuit after its stock price plummeted by over 50% following the United States===Food and Drug Administration's issuance of a Complete Response Letter for its lead drug candidate, relacorilant. The lawsuit, led by Kahn Swick & Foti, alleges that Corcept Therapeutics and its executives failed to disclose material information to investors regarding the drug's approval likelihood. The United States===Food and Drug Administration's decision indicated that additional evidence of effectiveness was required for a favorable benefit-risk assessment. Investors who purchased Corcept Therapeutics shares between October 31, 2024, and December 30, 2025, have until April 21, 2026, to file lead plaintiff applications.

Key Actions

100 Rosen Law Firm filed a class action lawsuit Corcept Therapeutics

100 Corcept Therapeutics stock price plummeted by 50.4%

95 United States===Food and Drug Administration issued Complete Response Letter for relacorilant NDA Corcept Therapeutics

90 Corcept Therapeutics made misrepresentations about drug approval

90 Corcept Therapeutics failed to disclose material information

85 Kahn Swick & Foti filed securities class action lawsuit Corcept Therapeutics

70 United States===Food and Drug Administration raised concerns about drug application Corcept Therapeutics

Entities Involved

stock

Corcept Therapeutics

Corcept Therapeutics is facing a securities class action lawsuit due to alleged misrepresentations regarding the approval likelihood of its drug relacorilant. The U.S. Food and Drug Administration issued a Complete Response Letter, causing a significant drop in Corcept Therapeutics's stock price.

Importance 100 Sentiment -70

govactor

United States===United States Food and Drug Administration

The United States===United States Food and Drug Administration issued a Complete Response Letter for Corcept Therapeutics' drug candidate, relacorilant, due to insufficient evidence of effectiveness. This action directly led to the significant drop in Corcept Therapeutics' stock price.

Importance 90 Sentiment 0

govactor

United States===Food and Drug Administration

The United States===Food and Drug Administration issued a Complete Response Letter for Corcept Therapeutics's New Drug Application for relacorilant, stating it could not arrive at a favorable benefit-risk assessment without additional evidence of effectiveness. This decision directly led to the stock price plummet and the subsequent lawsuit.

Importance 80 Sentiment 0

priv

Rosen Law Firm

Rosen Law Firm is initiating and representing investors in the class action lawsuit against Corcept Therapeutics, aiming to secure compensation for affected shareholders. This action enhances Rosen Law Firm's profile in securities litigation.

Importance 80 Sentiment 40

priv

Hagens Berman Sobol Shapiro LLP

Hagens Berman Sobol Shapiro LLP is a national shareholder rights law firm that filed the securities class action lawsuit against Corcept Therapeutics. The firm is actively urging investors to join the lawsuit and is leading the investigation into the alleged misconduct.

Importance 80 Sentiment 60

priv

The Schall Law Firm

The Schall Law Firm is representing investors in a class action lawsuit against Corcept Therapeutics. The firm is actively seeking investors who suffered losses during the specified Class Period.

Importance 80 Sentiment 20

priv

Hagens Berman

Hagens Berman, a national shareholder rights law firm, is representing investors in the class action lawsuit against Corcept Therapeutics. The firm is actively urging investors who suffered significant losses to contact them to discuss their rights and potentially become lead plaintiff.

Importance 80 Sentiment 70

+ 15 more entities View on Dashboard

Relationships

Charles Foti related ↔ Kahn Swick & Foti

Lewis Kahn related ↔ Kahn Swick & Foti

Corcept Therapeutics related ↔ Kahn Swick & Foti

Corcept Therapeutics related ↔ United States===Food and Drug Administration

Kahn Swick & Foti related ↔ United States===Food and Drug Administration

Rosen Law Firm related ↔ Corcept Therapeutics

Philip Kim related ↔ Rosen Law Firm

Lawrence Rosen related ↔ Rosen Law Firm

DJS Law Group related ↔ Corcept Therapeutics

United States===Food and Drug Administration related ↔ Corcept Therapeutics

+ 18 more relationships View on Dashboard

NEWSDESK

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard